Grey Street Capital’s GSK GSK Stock Holding History

Grey Street Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$407K	Buy	+9,412	New	+$388K	0.06%	334

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Grey Street Capital's GSK Position: Q1 2024 in Review

Grey Street Capital opened a new position in GSK (GSK) in Q1 2024: 9,412 shares worth $407K. The stake represents 0.06% of the portfolio and ranks #334 among its holdings.

911 funds tracked by Wall St. Rank hold GSK as of Q1 2024.

Grey Street Capital held 9,412 shares of GSK worth $407K as of Q1 2024.
GSK was a new Grey Street Capital position in Q1 2024.
GSK made up 0.06% of Grey Street Capital's portfolio in Q1 2024, its #334 holding.
911 funds tracked by Wall St. Rank held GSK as of Q1 2024.

Based on Grey Street Capital's 13F filing for Q1 2024, filed 9 Aug 2024.